Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Macrogenics (MGNX) Equity Ratio (2016 - 2025)

Historic Equity Ratio for Macrogenics (MGNX) over the last 14 years, with Q3 2025 value amounting to 0.25.

  • Macrogenics' Equity Ratio fell 4548.9% to 0.25 in Q3 2025 from the same period last year, while for Sep 2025 it was 0.25, marking a year-over-year decrease of 4548.9%. This contributed to the annual value of 0.44 for FY2024, which is 1326.87% down from last year.
  • According to the latest figures from Q3 2025, Macrogenics' Equity Ratio is 0.25, which was down 4548.9% from 0.19 recorded in Q2 2025.
  • Macrogenics' Equity Ratio's 5-year high stood at 0.8 during Q1 2021, with a 5-year trough of 0.19 in Q2 2025.
  • Its 5-year average for Equity Ratio is 0.52, with a median of 0.51 in 2023.
  • Per our database at Business Quant, Macrogenics' Equity Ratio tumbled by 5154.83% in 2023 and then surged by 3440.55% in 2024.
  • Macrogenics' Equity Ratio (Quarter) stood at 0.71 in 2021, then dropped by 29.16% to 0.51 in 2022, then increased by 1.0% to 0.51 in 2023, then decreased by 13.27% to 0.44 in 2024, then tumbled by 44.21% to 0.25 in 2025.
  • Its Equity Ratio stands at 0.25 for Q3 2025, versus 0.19 for Q2 2025 and 0.35 for Q1 2025.